Search hospitals > Tennessee > Memphis
St Jude Children's Research Hospital
Claim this profileMemphis, Tennessee 38105
Global Leader in Tumors
Global Leader in Brain Tumor
Conducts research for Leukemia
Conducts research for Lymphoma
Conducts research for Lymphoblastic Leukemia-Lymphoma
911 reported clinical trials
67 medical researchers
Summary
St Jude Children's Research Hospital is a medical facility located in Memphis, Tennessee. This center is recognized for care of Tumors, Brain Tumor, Leukemia, Lymphoma, Lymphoblastic Leukemia-Lymphoma and other specialties. St Jude Children's Research Hospital is involved with conducting 911 clinical trials across 825 conditions. There are 67 research doctors associated with this hospital, such as Alberto S. Pappo, Jeffrey E. Rubnitz, MD, PhD, Giles Robinson, MD, and Amar Gajjar, MD.Area of expertise
1Tumors
Global LeaderStage IV
Stage I
NTRK positive
2Brain Tumor
Global LeaderBRAF positive
NTRK positive
Stage IV
Top PIs
Alberto S. PappoSaint Jude Children's Research Hospital7 years of reported clinical research
Expert in Tumors
Expert in Rhabdomyosarcoma
23 reported clinical trials
41 drugs studied
Jeffrey E. Rubnitz, MD, PhDSt. Jude Children's Research Hospital4 years of reported clinical research
Expert in Leukemia
Expert in Acute Myeloid Leukemia
13 reported clinical trials
25 drugs studied
Giles Robinson, MDSt. Jude Children's Research Hospital8 years of reported clinical research
Studies Brain Tumor
Studies Medulloblastoma
13 reported clinical trials
29 drugs studied
Amar Gajjar, MDSt. Jude Children's Research Hospital4 years of reported clinical research
Studies Brain Tumor
Studies Astrocytoma
10 reported clinical trials
19 drugs studied
Clinical Trials running at St Jude Children's Research Hospital
Acute Myeloid Leukemia
Brain Tumor
Leukemia
Tumors
Acute Lymphoblastic Leukemia
Cancer
Neurofibromatosis
Myeloid Leukemia
Low Grade Glioma
Astrocytoma
Venetoclax + Chemotherapy
for Acute Myeloid Leukemia
This trial is testing whether adding venetoclax to standard chemotherapy can help young patients with relapsed AML. Venetoclax works by blocking a protein that helps cancer cells survive, making it easier for the chemotherapy to kill them. The study aims to find better treatment options for these patients who have limited choices. Venetoclax has been shown to improve overall survival in older and unfit patients with newly diagnosed acute myeloid leukemia when combined with lower intensity therapies.
Recruiting2 awards Phase 34 criteria
TCRγδ T Cells + Blinatumomab
for Blood Cancers
This study seeks to examine treatment therapy that will reduced regimen-related toxicity and relapse while promoting rapid immune reconstitution with limited serious graft-versus-host-disease (GVHD) and also improve disease-free survival and quality of life. The investigators propose to evaluate the safety and efficacy of selective naive T-cell depleted (by TCRɑβ and CD45RA depletion, respectively) haploidentical hematopoietic cell transplant (HCT) following reduced intensity conditioning regimen that avoids radiation in patients with hematologic malignancies that have relapsed or are refractory following prior allogeneic transplantation. PRIMARY OBJECTIVE: * To estimate engraftment by day +30 post-transplant in patients who receive TCRɑβ-depleted and CD45RA-depleted haploidentical donor progenitor cell transplantation following reduced intensity conditioning regimen without radiation. SECONDARY OBJECTIVES: * Assess the safety and feasibility of the addition of Blinatumomab in the early post-engraftment period in patients with CD19+ malignancy. * Estimate the incidence of malignant relapse, event-free survival, and overall survival at one-year post-transplantation. * Estimate incidence and severity of acute and chronic (GVHD). * Estimate the rate of transplant related mortality (TRM) in the first 100 days after transplantation.
Recruiting1 award Phase 221 criteria
Revumenib + Chemotherapy
for Acute Myeloid Leukemia
This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that did not go into remission after treatment (refractory) or has come back after treatment (relapsed), and to determine the total dose of the 3-drug combination of revumenib, azacitidine and venetoclax that can be given safely in participants also taking an anti-fungal drug. Primary Objective * To determine the safety and tolerability of revumenib + azacitidine + venetoclax in pediatric patients with relapsed or refractory AML or ALAL. Secondary Objectives * Describe the rates of complete remission (CR), complete remission with incomplete count recovery (CRi), and overall survival for patients treated with revumenib + azacitidine + venetoclax at the recommended phase 2 dose (RP2D).
Recruiting1 award Phase 110 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at St Jude Children's Research Hospital?
St Jude Children's Research Hospital is a medical facility located in Memphis, Tennessee. This center is recognized for care of Tumors, Brain Tumor, Leukemia, Lymphoma, Lymphoblastic Leukemia-Lymphoma and other specialties. St Jude Children's Research Hospital is involved with conducting 911 clinical trials across 825 conditions. There are 67 research doctors associated with this hospital, such as Alberto S. Pappo, Jeffrey E. Rubnitz, MD, PhD, Giles Robinson, MD, and Amar Gajjar, MD.
Where is St Jude Children's Research Hospital located?
St. Jude Children's Research Hospital is located at 262 Danny Thomas Place, Memphis, TN, approximately 10 miles southeast of downtown Memphis, near the Mississippi River.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at St. Jude Children's Research Hospital, the following contacts are available:
- **Financial Assistance**: Contact the Financial Assistance Department at 901-595-5466 or 901-595-0347 for concerns about hospital bill payments.
- **Patient Assistance Coordinator**: For financial support during treatment, resource connection, and insurance billing or payment questions, reach out to a patient assistance coordinator at 901-595-3957 or 901-438-2138.
- **Hospital Main Line**: For general inquiries, call 866-278-5833.
- **Revenue Integrity**: For insurance, pricing, or financial assistance questions, contact Danny Winchester at 901-595-2186 or email RevenueIntegrity@StJude.org.
What insurance does St Jude Children's Research Hospital accept?
St. Jude Children's Research Hospital accepts various insurance plans, covering treatment costs, copayments, deductibles, coinsurance, and any other costs not covered by insurance. The hospital does not bill patients, ensuring care is provided regardless of the ability to pay, through billing insurance plans or covering costs for uninsured patients. Patients are encouraged to review their insurance documents to understand coverage and consult their care team for any coverage concerns.
What awards or recognition has St Jude Children's Research Hospital received?
St. Jude Children's Research Hospital, located in Memphis, Tennessee, is renowned for its innovative Blue-Sky program, which has garnered over $50 million in funding for employee-generated projects. The hospital boasts a four-out-of-four star rating from Charity Navigator and has been recognized as one of America's Best Employers By State by Forbes in 2023.